

Preclinical Efficacy of the Auristatin-Based Antibody - Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors

Anette Sommer, Charlotte Kopitz, Christoph A. Schatz, et al.

Cancer Res 2016;76:6331-6339. Published OnlineFirst August 19, 2016.

Updated version	Access the most recent version of this article at: doi: 10.1158/0008-5472.CAN-16-0180
Supplementary Material	Access the most recent supplemental material at: http://cancerres.aacrjournals.org/content/suppl/2016/08/18/0008-5472.CAN-16-0180.DC1

Cited articles	This article cites 21 articles, 3 of which you can access for free at: http://cancerres.aacrjournals.org/content/76/21/6331.full#ref-list-1
Citing articles	This article has been cited by 3 HighWire-hosted articles. Access the articles at: http://cancerres.aacrjournals.org/content/76/21/6331.full#related-urls

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org .
Permissions	To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/76/21/6331 . Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.